Phase I study of ABBV|428
Study Details Page - Abbvie Clinical Trials
AbbVie Clinical Trials ... This website is designed to support, inform, and help patients interested in participating in a clinical trial, and is intended for use ...
Updated Safety and Efficacy Results of Abbv-383, a BCMA x CD3 ...
ABBV-383 has shown promising activity in an ongoing phase 1 study in patients (pts) with relapsed/refractory (RR) MM (Voorhees et al. ASH ...
A Phase 1 First-in-human Study to Investigate the Safety, Tolerability ...
By activating eIF2B, ABBV-CLS-7262 may attenuate the Integrated Stress Response and restore protein translation. Design/Methods: This multi-part Phase 1 study ...
Clinical Trials Using Anti-c-Met ADC ABBV-400 - NCI
Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help ...
M24-108: Phase 1b, Open-label Study with ABBV-383 in Relapsed ...
This is a study to determine adverse events and change in disease symptoms of ABBV-383 in adult participants with relapsed/refractory (R/R) MM.
Release Details - Regenxbio Inc
REGENXBIO Presents Positive Data from the Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD at AAO 2024 · 97% ...
A Phase 1 Study with ABBV-CLS-484 Alone and in Combination in ...
The study will assess the safety, PK, PD, and preliminary efficacy of ABBV-CLS-484 as monotherapy and in combination with a PD-1 targeting agent or with a ...
Mini oral session: NSCLC metastatic - OncologyPRO
A phase 1 study (NCT05029882) of ABBV-400 in adults with advanced solid tumors is ongoing; in dose escalation (N=57), ABBV-400 had a ...
ABBV-428 - Immuno-Oncology News
ABBV-428 is an investigational antibody-based cancer therapy, being developed by Abbvie and in a Phase 1 study to possibly treat solid tumors.
ABBV-400 for Advanced Solid Tumors - Clinical Trial - Duke Health
A Phase 1 first in human study evaluating safety, pharmacokinetics and efficacy of ABBV-400 in adult subjects with advanced solid tumors.
Release Details - Regenxbio Inc
REGENXBIO Announces Positive Interim Data from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal ...
First R/R Myeloma Patient Receives ABBV-383 - HealthTree
ABBV-383 is being evaluated in a phase 3 clinical trial called the Cervino study for myeloma patients whose disease returned or became resistant ...
MA 02.10 Phase I Study of ABBV-399 (Telisotuzumab Vedotin) as ...
A Phase II Study of Pembrolizumab in EGFR Mutant,. PD-L1+, Tyrosine Kinase ... Phase I Study of ABBV-399 (Telisotuzumab Vedotin) as. Monotherapy and in ...
Investigational drug ABBV-CLS-7262 initiates design phase for entry ...
BOSTON – The HEALEY ALS Platform Trial led by the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital in collaboration ...
Search for abbvie - EU Clinical Trials Register
The register also displays information on 18700 older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006). Phase 1 trials ...
A Phase 1 first-in-human study evaluating safety, pharmacokinetics ...
The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-706 as a monotherapy and in combination with ...
A Phase 1 Study of ABBV-453 in People with Recurrent or Persistent ...
Full Title First-in-Human Study of the BCL-2 Inhibitor ABBV-453 in Biomarker-Selected Subjects with Relapsed or Refractory Multiple Myeloma Purpose The ...
ABBV-400 Demonstrates Preliminary Efficacy, Safety in MSS/pMMR ...
The first-in-human phase 1 study is investigating the safety and antitumor activity of ABBV-400 in patients with advanced solid tumors.
Phase I study of ABBV-383, a BCMA×CD3 bispecific antibody, in R ...
Ravi Vij, MD, MBA, Washington University Medical School, St. Louis, MO, briefly comments on the results of a Phase I study evaluating ...